$LGND SEC Filings

Received 340 shares by exercise or conversion ($17.8K) · Sold 5,000 shares ($1.52M)

Gave up 115 shares to cover exercise price or tax ($34.3K)

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients

Sold 1,200 shares ($342K)

Sold 5,000 shares ($1.43M)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Received 31,641 shares by exercise or conversion ($1.8M) · Sold 31,641 shares ($9.24M)

Received 6,138 shares by exercise or conversion ($316K) · Sold 7,138 shares ($2.09M)

Received 5,000 shares by exercise or conversion ($261K) · Sold 5,000 shares ($1.44M)

Acquired 132 shares (Other Transaction) ($21.2K) · Received 5,000 shares by exercise or conversion ($261K) · Sold 5,000 shares ($1.57M)